Related Experiment Video
Updated: Sep 7, 2026
Isolation of Precursor B-cell Subsets from Umbilical Cord Blood
Published on: April 16, 2013
CD34 selection for purging in multiple myeloma and analysis of CD34+ B cell precursors
S Fruehauf1, R Haas, W J Zeller
1Department of Internal Medicine V, University of Heidelberg, Germany.
Abstract:
Selection of CD34+ hematopoietic progenitor cells from autografts may be performed in multiple myeloma (MM) to minimize contamination with tumor cells. This approach is based on the assumption that the malignant cells do not express the CD34 antigen. Therefore, we first compared the CD34+/CD10+ and CD34+/CD19+ subpopulations from bone marrow (BM) and peripheral blood (PB) of fourteen MM patients and five normal controls. No difference between the respective early B cell subsets of both groups could be observed. Using tricolor flow cytometry, the CD19 expression on CD34+/CD10+ cells in BM was found to increase continuously from CD19- to CD19dim. In contrast, circulating CD34+/CD10+ cells did not coexpress the CD19 antigen. This population may contain myeloid progenitor cells or bipotential progenitor cells of the myeloid and lymphoid lineage as suggested by data obtained with fetal liver cells. Further functional studies are required. Enrichment of CD34+ cells with immunomagnetic beads was performed from BM of three MM patients and four normal donors. The CD34+ cells were selected with the HPCA-1 antibody and detached from the beads with chymopapain. Compared with the starting cell preparation, a 3.97 +/- 0.48 log (mean +/- SE) reduction of plasma cells could be achieved after CD34 selection. On morphological examination, 84% +/- 4% of the cells in the CD34+ fraction (MM) were immature blasts. The plating efficiency for hematopoietic colony forming cells was 9.7% +/- 2.8% in the CD34 selected fraction of the MM group, reflecting a 51-fold increase as compared with the starting population.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
CD34 selection effectively reduces tumor cell contamination in multiple myeloma (MM) autografts. This process enriches for hematopoietic progenitor cells, crucial for stem cell transplantation.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Multiple myeloma (MM) treatment often involves autologous stem cell transplantation.
- Contamination of autografts with malignant plasma cells can negatively impact transplant outcomes.
- CD34+ hematopoietic progenitor cell selection is a strategy to purge tumor cells.
Purpose of the Study:
- To investigate the expression of CD19 on CD34+ cells in MM patients.
- To evaluate the efficacy of CD34+ cell selection in reducing plasma cell contamination in MM autografts.
- To assess the quality of CD34+ selected cells for hematopoietic recovery.
Main Methods:
- Flow cytometry was used to compare CD34+/CD10+ and CD34+/CD19+ subpopulations in bone marrow and peripheral blood of MM patients and controls.
- Immunomagnetic bead selection with the HPCA-1 antibody was employed to enrich CD34+ cells.
- Morphological examination and in vitro colony-forming assays were performed on selected cells.
Main Results:
- No significant difference in early B cell subsets (CD34+/CD10+, CD34+/CD19+) between MM patients and controls.
- CD19 expression on CD34+/CD10+ cells differed between bone marrow and peripheral blood.
- CD34+ cell selection achieved a significant reduction (approx. 4 log) in plasma cells.
- The CD34+ selected fraction contained immature blasts and demonstrated robust hematopoietic progenitor cell activity.
Conclusions:
- CD34+ cell selection is an effective method for purging plasma cells from MM autografts.
- The selected CD34+ cell product is enriched in hematopoietic progenitors, supporting engraftment.
- Further studies are needed to fully characterize the non-hematopoietic cell populations within the selected CD34+ fraction.
